Mikart, LLC, a US-based Contract Development and Manufacturing Organisation (CDMO), announced on Thursday that it has added Fette double-sided tablet presses to increase its production capacity and meet the product demands of its increasing number of customers.
The tablet presses have advanced features, which include automatic weight control, metal detectors, dedusters and bulk powder feeding systems for optimal efficiency and precision of tablet production applications.
Michael Kallelis, Mikart, LLC CEO, said, 'We are thrilled to expand our Fette tablet press platforms into our manufacturing operations. These high-speed and high-volume presses mark a significant milestone in our journey towards enhancing client satisfaction and accommodating the growing brand and generic market.'
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream